Abstract
A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.
| Original language | English |
|---|---|
| Pages (from-to) | 984-990 |
| Number of pages | 7 |
| Journal | British Journal of Cancer |
| Volume | 79 |
| Issue number | 5-6 |
| DOIs | |
| Publication status | Published - 1999 |
Fingerprint
Keywords
- Cisplatin
- Irinotecan
- Non-small-cell lung cancer
- Phase I study
- Small-cell lung cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Fractionated administration of irinotecan and cisplatin for treatment of lung cancer : A phase I study. / Ueoka, H.; Tabata, Masahiro; Kiura, Katsuyuki; Shibayama, T.; Gemba, K.; Segawa, Y.; Chikamori, K.; Yonei, T.; Hiraki, S.; Harada, M.
In: British Journal of Cancer, Vol. 79, No. 5-6, 1999, p. 984-990.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fractionated administration of irinotecan and cisplatin for treatment of lung cancer
T2 - A phase I study
AU - Ueoka, H.
AU - Tabata, Masahiro
AU - Kiura, Katsuyuki
AU - Shibayama, T.
AU - Gemba, K.
AU - Segawa, Y.
AU - Chikamori, K.
AU - Yonei, T.
AU - Hiraki, S.
AU - Harada, M.
PY - 1999
Y1 - 1999
N2 - A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.
AB - A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.
KW - Cisplatin
KW - Irinotecan
KW - Non-small-cell lung cancer
KW - Phase I study
KW - Small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=0033063624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033063624&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6690157
DO - 10.1038/sj.bjc.6690157
M3 - Article
C2 - 10070901
AN - SCOPUS:0033063624
VL - 79
SP - 984
EP - 990
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 5-6
ER -